Fig. 1From: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)Protocol overview. MRI: Magnetic resonance imaging; PDAC: Pancreatic duct adenocarcinoma; TDM TAP: CT-scan Thorax Abdomen and PelvisBack to article page